In her personal health column in the New York Times, Jane Brody writes that for consumers who are using direct-to-consumer genetic tests to discover their medical risks, testing is "fraught with potential dangers." Those dangers range from receiving false reassurance to a lack of federal oversight to uncertainty about clinical validity.